Table of Contents
July 01, 2003; Volume 70, Issue 7-
From the Editor
-
The promise of molecular biology: Efficacy, safety, wallet depletion
John D. Clough, MD- Cleveland Clinic Journal of Medicine July 2003, 70 (7) 584;
Molecular biology is entering its second wave, with effective but expensive treatments. Recombinant human parathyroid hormone (PTH) is a case in point.
-
-
Current Drug Therapy
-
Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosis
Chad Deal, MD and James Gideon, MD, PhD- Cleveland Clinic Journal of Medicine July 2003, 70 (7) 585-601;
We have an important new drug for osteoporosis. Now who should get it? And who will pay for it?
-
-
Im Board Review
-
A 34-year-old man with facial droop and dysarthria
James K. Stoller, MD, Ahmed Abdel Latif, MD, Hani Jneid, MD, Carlos M. Isada, MD and Gary S. Francis, MD- Cleveland Clinic Journal of Medicine July 2003, 70 (7) 602-613;
A previously well man develops flulike symptoms and neurologic deficits. What is the cause?
-
-
Review
-
Managing weight gain as a side effect of antidepressant therapy
Rashmi Deshmukh, MD and Kathleen Franco, MD- Cleveland Clinic Journal of Medicine July 2003, 70 (7) 314-623;
Some drugs are more apt to cause weight gain than others; one should inform and work with the patient.
-
Amiodarone-induced thyrotoxicosis: Diagnostic and therapeutic strategies
Gustavo A. Cardenas, MD, José M. Cabral, MD and Camilo A. Leslie, MD, MBA- Cleveland Clinic Journal of Medicine July 2003, 70 (7) 624-631;
It is difficult but important to distinguish the two types of amiodarone-induced thyrotoxicosis.
-
-
Commentary
-
Are we winning or losing the war on cancer?
Maurie Markman, MD- Cleveland Clinic Journal of Medicine July 2003, 70 (7) 632-633;
The news from the cancer front is good and bad.
-
-
Review
-
Using C-reactive protein to assess cardiovascular disease risk
Mehdi H. Shishehbor, DO, Deepak L. Bhatt, MD and Eric J. Topol, MD- Cleveland Clinic Journal of Medicine July 2003, 70 (7) 634-640;
CRP is now a recognized cardiac test. But who should he tested?
-
New advances transform the management of women with abnormal Pap tests
Xian Wen Jin, MD, PhD, Craig Nielsen, MD, Jennifer Brainard, MD and Belinda Yen-Lieberman, PhD- Cleveland Clinic Journal of Medicine July 2003, 70 (7) 641-648;
We review the new thin-layer slide system, the new HPV test, the 2001 reporting system for Pap tests, and new management guidelines.
-
-
Interpreting Key Trials
-
In refractory temporal lobe epilepsy, consider surgery sooner
Redeepak Lachhwani, MB, BS, MD and Hans Lüders, MD, PhD- Cleveland Clinic Journal of Medicine July 2003, 70 (7) 649-653;
Epilepsy surgery is perhaps the most underused therapy in all of medicine today.
-
